Chronic hepatitis C virus (HCV) infection, an important cause of morbidity and mortality worldwide, is a significant problem in kidney transplant recipients (KTRs) given its high prevalence in patients undergoing hemodialysis. Interferon based regimens were cornerstone of treatment of HCV infection in the past; however, due to their low efficacy and high rates of adverse effects, they have been abandoned in the new era of direct acting antivirals (DAAs). Several studies demonstrated the efficacy and safety of DAAs, yet data regarding clinical practice of these agents in KTRs is still needed. Therefore, we conducted a study using our registry data to evaluate the efficacy and safety of DAAs in KTRs.
Study Type
OBSERVATIONAL
Enrollment
30
Istanbul University
Istanbul, Turkey (Türkiye)
SVR12
Undetectable levels of HCV RNA for 12 weeks after the end of treatment with direct acting antivirals.
Time frame: 6 months
Stable Graft Function
Stability of serum creatinine and proteinuria levels of kidney transplant recipients during and after the treatment with direct acting antivirals.
Time frame: 6-12 months
Stable Serum Trough Levels of Immunosuppressive Agents
Stability of serum trough levels of calcineurin and mTOR inhibitors during the treatment with direct acting antivirals.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.